Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Eur Urol Focus. 2020 Mar 15;6(2):255-258. doi: 10.1016/j.euf.2020.01.008. Epub 2020 Feb 6.
The five-tier grade group (GG) classification for prostate cancer (PCa) does not differentiate between primary (5+4) or secondary (4+5) histological Gleason 5 pattern in GG 5. We addressed the prognostic value of primary versus secondary biopsy Gleason 5 for GG 5 among 18 555 PCa patients treated with radical prostatectomy (RP) between 1992 and 2014. Of these, 922 patients had GG 5 PCa with primary (n=295) or secondary (n=627) Gleason 5 on biopsy. Prediction of biochemical recurrence (BCR), metastasis, and cancer-specific mortality (CSM) was assessed using Kaplan-Meier curves and univariable/multivariable Cox regression controlling for known prognosticators. Median follow-up was 74.8 mo (interquartile range [IQR] 49.2-120.2). BCR developed in 24.3% of patients (n=4508) at a median of 23.6 mo (IQR 7.1-48.6). Metastasis developed in 4.5% (n=827) and 2.0% (n=370) died of PCa. When stratifying GG 5 by primary versus secondary Gleason 5, the estimated 5-yr metastasis-free survival was 80.4% (95% confidence interval [CI] 76.1-85.0%) versus 86.9% (95% CI 84.2-89.7%; p= 0.002) and cancer-specific survival was 90.9% (95% CI 87.5-94.4%) versus 96.3% (95% CI 94.7-98.0%; p< 0.001). On multivariable analysis, the negative impact of primary biopsy Gleason 5 among GG 5 patients remained significant for metastasis (hazard ratio [HR] 1.58; p< 0.001) and CSM (HR 2.44; p< 0.001). Therefore, stratifying GG 5 into primary (5 + 4, 5 + 5) and secondary (4 + 5) Gleason 5 may be warranted. PATIENT SUMMARY: We recorded worse oncological outcomes for patients with a primary histological Gleason 5 pattern on prostate biopsy compared to patients with a secondary biopsy Gleason 5 pattern.
前列腺癌(PCa)的五级分组(GG)分类不能区分 GG5 中原发性(5+4)或继发性(4+5)组织学 Gleason5 模式。我们针对 1992 年至 2014 年间接受根治性前列腺切除术(RP)治疗的 18555 例 PCa 患者,研究了 GG5 中原发性与继发性活检 Gleason5 对 GG5 的预后价值。其中,922 例患者 GG5 PCa 中,原发性(n=295)或继发性(n=627)活检中有 Gleason5。使用 Kaplan-Meier 曲线和单变量/多变量 Cox 回归分析评估生化复发(BCR)、转移和癌症特异性死亡率(CSM),并控制已知的预后因素。中位随访时间为 74.8 个月(四分位距 [IQR] 49.2-120.2)。24.3%的患者(n=4508)发生 BCR,中位时间为 23.6 个月(IQR 7.1-48.6)。4.5%(n=827)发生转移,2.0%(n=370)死于 PCa。当按原发性与继发性 Gleason5 对 GG5 进行分层时,估计 5 年无转移生存率为 80.4%(95%CI 76.1-85.0%)与 86.9%(95%CI 84.2-89.7%;p=0.002),癌症特异性生存率为 90.9%(95%CI 87.5-94.4%)与 96.3%(95%CI 94.7-98.0%;p<0.001)。多变量分析显示,GG5 患者原发性活检 Gleason5 对转移(危险比 [HR] 1.58;p<0.001)和 CSM(HR 2.44;p<0.001)的负面影响仍然显著。因此,将 GG5 分为原发性(5+4,5+5)和继发性(4+5)Gleason5 可能是必要的。
与 GG5 中存在继发性活检 Gleason5 模式的患者相比,我们记录到原发性组织学 Gleason5 模式患者的肿瘤学结局更差。